Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965149 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1964533 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2167109 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2220843 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16903363 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16903366 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16903369 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL18084814 | 0.91 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16903380 | 0.91 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16903383 | 0.91 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264134-B2 | Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3886845-B1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118388454-A | Modulators of BCL6 proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-4323352-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-3558310-B1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117279910-A | Modulators of BCL6 proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
| CN-115243687-A | N- (heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions and uses thereof | 默沙东有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| US-11319298-B2 | Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20110184013-A1 | Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors | ARRAY BIOPHARMA, INC. | 2011-07-28 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
| EP-2334677-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| CN-101835764-A | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC | 2010-09-15 | — | — | CN | disclosed |
| US-20100210623-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-08-19 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010039825-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010022076-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210623-A1 | THERAPEUTIC COMPOUNDS | JAK2, PDK1, JAK3 | SMN1; SMN2 3959/4885NPC1 3966/4885RAB9A 2950/4885 |
| US-11319298-B2 | Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM4, CHRM2, CHRM5 | SMN1; SMN2 3113/4885NPC1 2559/4885RAB9A 2254/4885 |
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | SMN1; SMN2 4457/4885NPC1 4398/4885RAB9A 2050/4885 |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | SMN1; SMN2 3055/4885NPC1 1917/4885RAB9A 2933/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | SMN1; SMN2 3213/4885NPC1 4144/4885RAB9A 4223/4885 |
| US-12264134-B2 | Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, AADAC | SMN1; SMN2 2974/4885NPC1 2094/4885RAB9A 3024/4885 |
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | SMN1; SMN2 2465/4885NPC1 2309/4885RAB9A 3365/4885 |
| US-20110184013-A1 | Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors | PIM1, PIM2, PIM3 | SMN1; SMN2 4336/4885NPC1 3350/4885RAB9A 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.